Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6139500 | 0.77 | PARP1 (0.55) | PARP1 | |
| SCHEMBL6139121 | 0.73 | PARP1 (0.63) | PARP1 | |
| SCHEMBL27572635 | 0.73 | ALDH1A1 (0.39) | PARP1CNR1CNR2 | |
| SCHEMBL12750844 | 0.72 | PARP1 (0.51) | PARP1 | |
| SCHEMBL16420447 | 0.69 | CNR1 (0.47) | CNR1CNR2AKT1 | |
| SCHEMBL3892253 | 0.69 | OPRM1 (0.45) | CNR1CNR2AKT1 | |
| SCHEMBL2554955 | 0.69 | AKT1 (0.47) | CNR1CNR2AKT1 | |
| SCHEMBL16418423 | 0.69 | GRIN2D (0.50) | CNR1CNR2AKT1 | |
| SCHEMBL6139770 | 0.68 | PARP1 (0.59) | PARP1 | |
| Hydrochloric Acid SCHEMBL27552695 | 0.68 | OPRM1 (0.44) | CNR1CNR2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979683-B2 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-SYNTHELABO (FR) | 2005-12-27 | — | — | US | disclosed |
| EP-1339719-B1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-20040029866-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029866-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, CBR1, NR3C1 | PARP1 1683/4885CNR1 9/4885CNR2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.